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Over the past few years, an increasing number of articlesin peer-reviewed journals have detailed various ap-
proaches of high-precision radiation therapy (RT) that use the
most sophisticated methods of target definition, treatment
planning, and external beam or single-dose intraoperative or
brachytherapy techniques. The concept of precision has often
been associated with the use of accelerated schedules of
fractionation, mainly hypofractionation. Lung cancer is the
leading cause of cancer deaths worldwide. Although surgical
removal of lung cancer is the standard treatment, many patients
cannot undergo surgery because of advanced age, poor medical
condition, and/or insufficient lung capacity.
The standard treatment for inoperable but localized
lung cancer is RT alone or combined with drugs. The stan-
dard RT dose is defined as 60 Gy in 30 daily fractions. After
standard RT and chemotherapy, increased but unsatisfactory
local control rates have generally been observed. Based on
dose-response data, it seems that higher doses and/or shorter
treatment times would be required to achieve better disease
control.1 Technologies that could be helpful in accomplishing
these goals include the use of three-dimensional planning and
RT, intensity-modulated RT (IMRT), stereotactic radiosur-
gery, and other special devices or techniques, such as tomo-
therapy or hadrontherapy.2,3
THE ROLE OF BIOLOGICAL IMAGING IN
PRECISION RT TECHNIQUES
Precision RT requires accurate tumor identification and
delineation. Computed tomography (CT) anatomic imaging
remains the reference modality for treatment planning, but
the use of magnetic resonance (MRI) has allowed better
target volume definition than CT in some specific sites and
has provided multiplane images, facilitating the assessment
of tumor extension. Progress in biological imaging, mostly
based on positron emission tomography (PET) and MR-
spectroscopy, may allow clinicians to incorporate functional
images in RT practice on a regular basis. PET is currently
used in oncology for staging, follow-up, and, to a limited
degree, the assessment of therapy response. So far, attention
has been focused mainly on imaging of glucose uptake with
fluoro-2-deoxy-D-glucose (FDG). However, beyond these
applications, there are new areas for the use of PET that may
result in significant improvement for tumor treatment. Indeed,
assessment of the biochemical and functional features of
tumors by PET may allow the definition of local features that
can be exploited to focus on the treatment strategies. More-
over, by using the most recent PET-CT scanners that allow
concurrent assessment of morphology and function, it is
possible to mechanically co-register images obtained during
the same scanning session, without delays and time lag that
may reduce the usefulness and interpretability of the co-
registered morphologic and functional information. Tumor
masses are never homogeneous with respect to many features
that may or may not appear on CT images only as variations
in tissue density, including viability and necrosis, vascular-
ization and oxygenation, rate of cellular growth, and apopto-
sis. All these features account for the malignancy and evolu-
tion of the tumor, its aggressiveness, and its spread. Their
assessment could be extremely useful for precision radiation
therapy planning. Thus, the idea of achieving tumor tissue
characterization by PET has become a major goal, enhancing
the precision with which modern RT modalities are delivered
to patients. PET reduces the likelihood of topographic mis-
locations, allowing for dose escalation and increased delivery
to the more radioresistant tumor areas, hopefully improving
the chance of achieving local control.4 For example, among
patients with non-small cell lung cancer, the use of FDG-PET
helps to exclude areas of atelectasia or infection from the
target volume on the one hand; on the other hand, the use of
FDG-PET leads to an increase of the treated volume so as to
incorporate regional lymph node lesions detected because of
their FDG uptake.5,6
IMAGE-GUIDED RT
Image-guided RT (IGRT) helps to better deliver the
radiation dose to the lung cancer. Normal tissue and tumors
can move during treatments because of the differences in
organ filling or, as in case of lung cancer, because of move-
ments during patient breath. IGRT can be used for all the RT
high-precision techniques because it allows the best confor-
mality index during treatment. Irradiation is guided by real-
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time imaging equipment, such as CT-scan, stereoscopic ra-
diographs, or megavoltage devices, taken in the treatment
room just before the delivery of the daily dose. IGRT in-
volves a CT scan or CT/PET hybrid machine and computer
modeling to accurately determine the size and depth of the
tumor. The digital information is then transmitted to the
console in the treatment room to compare the reference
images with those taken just before treatment; the “fusion” of
these images shows whether the patient’s position needs to be
changed to avoid geographic misses of the tumor or unnec-
essary healthy tissue exposure. Improvement in the accuracy
of patient positioning and evaluation of the organ motion
ensures that the potential benefits of high-precision RT,
especially IMRT, applied to lung cancer are transferred to the
reality of each irradiation section. This is the concept of the
adaptive RT process. The implantation of a tiny piece of
radiopaque material called “fiducial marker” near or in the
tumor mass helps to localize the target. Noninvasive systems,
which include opto-electronic localization systems with re-
flective markers positioned in well-defined skin landmarks,
are also available. In addition to static assessment of tumor
location and patient position, dynamic image acquisition
determines the measurement of the tumor mass through all
stages of respiration and can direct the radiation more pre-
cisely while the patient is breathing normally. This may be
important for many of these patients who have poor lung
function, as they are unable to hold their breath during
treatment.
IGRT permits dose-escalation studies using three-
dimensional planning in a safe manner, and this is an impor-
tant advance, as targeting errors previously occurred in up to
30% of patients in cooperative group trials.3 Investigating the
findings of the Memorial Sloan-Kettering Cancer Center,
University of Michigan, and RTOG trials, we can see that the
maximal dose administered ranged from 84 to 102.9 Gy for
small tumors (peripheral coin lesions), 75.6 to 84 Gy for
medium tumors (4 cm or larger with hilar or limited medi-
astinal adenopathy), and 65.1 to 84 Gy for large tumors. High
values of V20 have been correlated with increased risk of
pneumonitis.7 Recent three-dimensional RT dose-escalation
studies targeted gross disease alone and included concurrent
chemotherapy. Two separate phase I trials, one performed by
the RTOG (L-0117) and the other performed by NCCTG
(N0028), determined that 74 Gy in 37 daily fractions was the
maximal tolerated dose when administered weekly with con-
current carboplatin and paclitaxel.8,9
IMRT is a specialized form of conformal RT that
allows radiation to be more shaped. With IMRT, the beam
can be broken up into multiple beamlets of varying intensity.
Planning is generally performed with inverse systems and
delivered with dynamic multileaf collimators that actively
vary the field shape during RT. IMRT plans are often asso-
ciated with better tumor coverage and sparing of normal
tissues, with a median reduction in the volume of lung
receiving greater than or equal to 20 Gy (V20) of 10% when
compared with three-dimensional treatment planning.10
Other Innovations Include Tomotherapy, Sterotactic
RT, and Hadron Therapy.
Helical tomotherapy allows the delivery of IMRT using
a linear accelerator that rotates around the patient in a continuous
helix, similar to a CT scanner. Tomotherapy treatment seems to
decrease the doses administered to the normal tissues and could
allow the safe delivery of a greater dose to the tumor volume.11
One additional advantage of this unit is the ability to image the
patient during therapy and evaluate the location of the tumor to
prevent geographic misses.
Stereotactic RT has been used to treat early-stage non-
small cell lung cancer with favorable preliminary results. An
interesting feature of this technique is the use of high doses
per fraction. Doses of greater than or equal to 18 Gy per
fraction guarantee a good rate of local control.12 Using this
technique, the RTOG has initiated a phase II trial (RTOG
L-0236) for select patients with early-stage medically inop-
erable NSCLC. The CyberKnife system has also been used to
perform stereotactic RT for lung tumors.13 The CyberKnife is
a frameless system that includes a 6-MV linear accelerator
mounted on a computer-controlled robotic arm. The system
also uses IGRT technology.
Hadron therapy provides the use of protons or heavy
ions. Potential radiobiological advantages of hadrons include
high ballistic level and, for carbon ions, higher relative
biological effectiveness. Preliminary experiences in treating
patients with unresectable stage I non-small cell lung cancer
are extremely encouraging for both protons14 and ions.15
CONCLUSIONS
Radiation plays a key role in the treatment of lung
cancer. Recent innovations include altered fractionation
schedules, three-dimensional treatment planning, IMRT, ste-
reotactic RT, and hadron therapy. All these technologies are
based on the concept of IGRT. Recent data suggest that
newer techniques may enhance the outcome of patients with
lung cancer by improving local control rates and minimizing
side effects.
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